Upsher Smith Labs Company Profile
✉ Email this page to a colleague
What is the competitive landscape for UPSHER SMITH LABS, and what generic alternatives to UPSHER SMITH LABS drugs are available?
UPSHER SMITH LABS has ninety-two approved drugs.
There are eight US patents protecting UPSHER SMITH LABS drugs.
There are seventeen patent family members on UPSHER SMITH LABS drugs in ten countries and one hundred and thirty-seven supplementary protection certificates in thirteen countries.
Summary for Upsher Smith Labs
International Patents: | 17 |
US Patents: | 8 |
Tradenames: | 71 |
Ingredients: | 65 |
NDAs: | 92 |
Drugs and US Patents for Upsher Smith Labs
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Upsher Smith Labs | BACLOFEN | baclofen | TABLET;ORAL | 074584-002 | Aug 19, 1996 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
Upsher Smith Labs | BUMETANIDE | bumetanide | TABLET;ORAL | 209916-001 | Jan 23, 2018 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
Upsher Smith Labs | CLOBAZAM | clobazam | TABLET;ORAL | 209687-002 | Oct 22, 2018 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
Upsher Smith Labs | JANTOVEN | warfarin sodium | TABLET;ORAL | 040416-009 | Oct 2, 2003 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
Upsher Smith Labs | KLOR-CON | potassium chloride | TABLET, EXTENDED RELEASE;ORAL | 019123-001 | Apr 17, 1986 | AB2 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Upsher Smith Labs
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Upsher Smith Labs | FORTICAL | calcitonin salmon recombinant | SPRAY, METERED;NASAL | 021406-001 | Aug 12, 2005 | 6,440,392 | ⤷ Subscribe |
Upsher Smith Labs | FORTICAL | calcitonin salmon recombinant | SPRAY, METERED;NASAL | 021406-001 | Aug 12, 2005 | RE40812 | ⤷ Subscribe |
Upsher Smith Labs | FORTICAL | calcitonin salmon recombinant | SPRAY, METERED;NASAL | 021406-001 | Aug 12, 2005 | RE43580 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for UPSHER SMITH LABS drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Nasal Spray | 200 IU/spray | ➤ Subscribe | 2006-03-29 |
➤ Subscribe | Extended-release Capsules | 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg | ➤ Subscribe | 2015-12-24 |
International Patents for Upsher Smith Labs Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Australia | 2014362275 | ⤷ Subscribe |
European Patent Office | 3079703 | ⤷ Subscribe |
South Korea | 20160124930 | ⤷ Subscribe |
South Korea | 102072618 | ⤷ Subscribe |
World Intellectual Property Organization (WIPO) | 2014143380 | ⤷ Subscribe |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Upsher Smith Labs Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2932970 | 1890039-9 | Sweden | ⤷ Subscribe | PRODUCT NAME: DOLUTEGRAVIR SODIUM + RILPIVIRINE HYDROCHLORIDE; REG. NO/DATE: EU/1/18/1282 20180518 |
2924034 | 1990024-0 | Sweden | ⤷ Subscribe | PRODUCT NAME: DORAVIRINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF IN COMBINATION WITH LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE; REG. NO/DATE: EU/1/18/1333 20181126 |
2822954 | LUC00083 | Luxembourg | ⤷ Subscribe | PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM; AUTHORISATION NUMBER AND DATE: EU/1/18/1289 20180625 |
1441735 | SPC/GB08/020 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: RALTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT; REGISTERED: UK EU/1/07/436/001 20080102 |
2822954 | SPC/GB18/031 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM.; REGISTERED: UK EU/1/18/1289/001(NI) 20180625; UK EU/1/18/1289/002(NI) 20180625; UK PLGB 11972/0008 20180625 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.